Allergen Aesthetics announced that the U.S. Food and Drug Administration (FDA) has approved its minimally invasive, hyaluronic acid intradermal microdroplet injection (Skinvive by Juvéderm) as a skin-smoothing agent. Researchers explained that the novel injection consists of hyaluronic acid gel containing the anesthetic lidocaine and is designed to smooth the skin of the cheeks after facial injection in all Fitzpatrick skin types. Further, the smoothing effects have been shown to persist for up to 6 months and patients have reported experiencing a “lasting glow”—which the researchers have clinically verified. In two separate studies, researchers found that 55.6% (n = 69/124) of the patients who received the novel injection demonstrated improvements in skin hydration—marked by elevated levels of aquaporin—as well as gains per the Allergen Cheek Smoothness Scale after 6 months of follow-up. Additionally, 63%, 69%, 72%, and 83% of patients reported feeling satisfied with their skin’s radiance, rejuvenation, hydration, and healthiness, respectively, after the conclusion of the 6-month period. Despite the positive results, the researchers warned that patients may experience side effects from the agent such as itchiness, redness, tenderness, firmness, bumps, swelling, discoloration, or pain within 30 days of injection. Individuals who are considering a smoothing agent for their cheeks were advised to speak to their dermatologists.
May 18, 2023